CClinicalTrials.gg
Sign In
TerminatedNCT02890875Updated May 2, 2019

Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

An interventional study of Ethanol lock and Heparin lock in Catheter-Related Infections, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-02.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

Why this study was terminated
Low recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients on long-term parenteral nutrition (PN) are at high risk for central line-associated bloodstream infections (CLABSI). This study evaluates the efficacy and safety of ethanol lock therapy for CLABSI prophylaxis in adult patients on PN.

02

Conditions studied

  • Catheter-Related Infections

Keywords

  • ethanol lock
  • parenteral nutrition
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 3 is below the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients (ages 18-80) on PN with silicone-based central venous catheters

Exclusion criteria

Exclusion Criteria:

  • Weight ≤ 50 kg
  • Allergy/hypersensitivity/intolerance to ethanol or heparin
  • Pregnancy or breastfeeding
  • Patient taking metronidazole, disulfiram, or isoniazid
  • History of alcohol abuse
  • History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable state
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Ethanol lock

    70% ethanol

    Other: Ethanol lock

  • Active comparator
    Heparin lock

    Heparinized saline (100 U/mL)

    Other: Heparin lock

Interventions

  • OtherEthanol lock
  • OtherHeparin lock
06

What researchers measure

Primary outcomes

  1. Central line-associated bloodstream infection

    Time frame: 12 months

Secondary outcomes

  1. Hospitalization

    Time frame: 12 months

  2. SIRS/sepsis

    Time frame: 12 months

  3. Catheter-related complication

    Time frame: 12 months

  4. New self-reported symptoms

    Time frame: 12 months

Other outcomes

  1. Microorganism (blood culture, if obtained for clinical reasons)

    Time frame: 12 months

07

Study locations

1 site
  • Stanford University
    Palo Alto, California 94304, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02890875
Lead sponsor
Stanford University
Responsible party
Berkeley Limketkai (Clinical Assistant Professor, Stanford University) — Principal investigator
First posted
Sep 7, 2016
Start date
Aug 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
May 2, 2019

Study contacts

Berkeley Limketkai, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

Stanford University

Start the discussion